MedTrace Logo

Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease Study

NCT00053599 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2009-07-28

No results posted yet for this study

Summary

CLASP is a research study to investigate the safety and effectiveness of simvastatin (a cholesterol lowering drug or statin) to slow the progression of Alzheimer's disease (AD). Statins are commonly used to treat high cholesterol levels, which increase the risk of heart disease and stroke.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Simvastatin

Sponsors & Collaborators

  • Alzheimer's Disease Cooperative Study (ADCS)

    collaborator OTHER

  • National Institute on Aging (NIA)

    lead NIH

Principal Investigators

  • Mary Sano, PhD · Icahn School of Medicine at Mount Sinai

  • Leon J. Thal, MD · University of California, San Diego

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2007-10-31
Completion
2007-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00053599 on ClinicalTrials.gov